ClinicalTrials.gg
RecruitingNCT07718672Updated Nov 5, 2026

Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer

A Phase 2 interventional study of Biospecimen Collection and Computed Tomography in Early Stage Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8 and Stage II Lung Cancer AJCC v8, sponsored by Roswell Park Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Roswell Park Cancer Institute · Phase 2, Interventional, and Treatment

How we know

Updated Nov 5, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 36 studies in Lung Neoplasms by Roswell Park Cancer Institute — 9 open to participants now, 11 under way, 1 of them phase 3. Lung Neoplasms · Roswell Park Cancer Institute.

Planned enrollment
4th of 31
200 · median 38
Started
2026
with 5 others
Phase 2
13 of 36
4 open now
Primary completion
2029-06
later than 8 of 10 live
Registered
36th of 36
by date

Among the 36 studies in Lung Neoplasms by Roswell Park Cancer Institute, this one is the 4th largest by planned enrollment of the 31 interventional ones that give a count, is one of 6 that started in 2026, is one of 13 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 36th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

9 of the 36 studies in Lung Neoplasms by Roswell Park Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Lung Neoplasms by Roswell Park Cancer Institute, or all of them as a file.
02

Study summary

This clinical trial compares stereotactic ablative radiotherapy (SBRT) with hot spots to standard of care SBRT for the treatment of patients with early-stage non-small cell lung cancer. SBRT with hot spots intentionally makes sure the tumor gets a higher radiation dose during treatment. This potentially may result in better control of the tumor, but also more side effects. SBRT with or without hot spots may be more effective in treating patients with early-stage non-small cell lung cancer, compared to standard of care SBRT.

Read the detailed description

PRIMARY OBJECTIVE:

I. Evaluate the impact of incorporating high isodoses termed "hot spots" in radiation therapy planning on local control.

SECONDARY OBJECTIVES:

I. Evaluate the impact of "hot spots" in radiation therapy planning on progression-free survival (PFS).

II. Evaluate the impact of "hot spots" in radiation therapy planning on overall survival (OS).

III. Evaluate the impact of tumor size on local control and if hotspot grouping impacts local control in a size-dependent manner.

IV. To prospectively evaluate the PFS in early stage-non small cell lung cancer (ES-NSCLC) patients undergoing SABR who are already taking a beta-blocker as well as a potential interaction between beta-blocker usage and the perceived stress scale.

V. Will evaluate for any potential interactions between quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer [EORTC QLQ-LC13]) and hotspot grouping.

VI. Evaluate the impact of "hot spots" in radiation therapy planning on toxicity by total number of grade 3+ adverse effects.

EXPLORATORY OBJECTIVE:

I. Change in immune cell marker levels at week 12 post-SBRT (± 1 week) versus baseline, such as mediators of tumor antigen presentation, costimulatory molecules, immune effector cell populations, including CD4+ and CD+8 T-cells, T regulatory cells (CD4+CD25+FoxP3+), natural killer (NK) cells, monocytes, macrophages, dendritic cells (DCs) and myeloid derived suppressor cells (MDSCs).

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive standard of care (SOC) SBRT for 1-5 fractions over 1-11 days, in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan with or without positron emission tomography (PET) scan and blood sample collection throughout the study. Patients may undergo lymph node sampling throughout the study.

ARM II: Patients receive hot spot SBRT for 1-5 fractions over 1-11 days, in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan with or without PET scan and blood sample collection throughout the study. Patients may undergo lymph node sampling throughout the study.

After completion of study treatment, patients are followed up every 3 months for 1 year and then every 3-6 months up to month 36.

03

Conditions studied

  • Early Stage Lung Non-Small Cell Carcinoma
  • Stage I Lung Cancer AJCC v8
  • Stage II Lung Cancer AJCC v8

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Have an (ECOG) performance status of ≤ 2
  • Diagnosed with T1-3N0 -proven NSCLC of the lung. Multiple primary lung tumors are allowed; however, each lesion requires histologic confirmation
  • Metachronous lung tumors as defined as a new lung lesion in the setting of a historically treated lung cancer are allowed under certain conditions. The previous lung cancer must have been treated greater than 6 months prior to protocol therapy and this cancer must be considered controlled
  • Eligible for SABR
  • Participants of must agree to use adequate methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • Participant must understand the nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written form prior to receiving any study related procedure

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of a prior lung cancer will be excluded only if the previous treatment is within 6 months of the protocol therapy
  • Mixed small cell and non-small cell lung cancer
  • History of allogeneic organ transplantation
  • History of primary immunodeficiency
  • Patients must not have undergone prior radiation to overlapping regions of the chest that, in the opinion of the treatment physician, will interfere with protocol treatment
  • Active disease that has required systemic treatment in the last 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiologic replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
  • Known EGFR or ALK mutation
  • Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD
  • Pregnant or nursing female participant
  • Unwilling or unable to follow protocol requirements
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Aim II (hot spot SBRT)

    Patients receive hot spot SBRT for 1-5 fractions over 1-11 days, in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan with or without PET scan and blood sample collection throughout the study. Patients may undergo lymph node sampling throughout the study.

    Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Lymph Node Biopsy · Procedure: Positron Emission Tomography · Radiation: Stereotactic Body Radiation Therapy · Other: Survey Administration

  • Experimental
    Arm I (SOC SBRT)

    Patients receive SOC SBRT for 1-5 fractions over 1-11 days, in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan with or without PET scan and blood sample collection throughout the study. Patients may undergo lymph node sampling throughout the study.

    Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Lymph Node Biopsy · Procedure: Positron Emission Tomography · Radiation: Stereotactic Body Radiation Therapy · Other: Survey Administration

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • ProcedureLymph Node Biopsy

    Undergo lymph node sampling

    Also known as: Biopsy of Lymph Node

  • ProcedurePositron Emission Tomography

    Undergo PET scan

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

  • RadiationStereotactic Body Radiation Therapy

    Receive SOC SBRT

    Also known as: SABR, SBRT, Stereotactic Ablative Body Radiation Therapy

  • RadiationStereotactic Body Radiation Therapy

    Receive hot spot SBRT

    Also known as: SABR, SBRT, Stereotactic Ablative Body Radiation Therapy

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Time to progression (local control)

    Defined as no failure within the radiotherapy planning target volume (PTV), based on the international consensus on assessing local failure after stereotactic ablative radiotherapy (SBRT) will be utilized. The 2-year local control rates will be summarized by treatment arms using 90% Clopper-Pearson confidence intervals. The local control rates between arms will be compared using one-sided Cochrane-Mantel-Haenszel test (alpha=0.1), stratified by performance status, surgery candidacy, and beta-blocker usage.

    Time frame: Up to 2 years

Secondary outcomes

  1. Progression free survival (PFS)

    Will be summarized by treatment arms using the Kaplan-Meier product limit estimator.

    Time frame: From the start of treatment to first documented disease progression, or death due to any cause, up to 3 years

  2. Overall survival (OS)

    Will be summarized by treatment arms using the Kaplan-Meier product limit estimator. One-sided log-rank test stratified by tumor size, performance status, and surgery candidacy will be used to compare the OS between treatment arms (alpha=0.1).

    Time frame: From the start of treatment to patient death due to any cause, up to 3 years

  3. Time to progression (local control) in a size-dependent manner

    Defined as no failure within the radiotherapy PTV, based on the international consensus on assessing local failure after SBRT will be utilized.

    Time frame: Up to 3 years

  4. PFS for patients who are already taking a beta blocker

    Time frame: Up to 3 years

  5. Perception of Stress using Perceived Stress Scale

    Will be measured by The Perceived Stress Scale (PSS) which assesses the perception of stress. The scale is constituted by 10 items that are self-rated by the subject on a 0-4 Likert scale. The scale minimum total score is 0, the maximum is 40. Higher total scores indicate a worse outcome

    Time frame: Up to 3 years

  6. Change in Quality of life

    Assessed via European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer.

    Time frame: Up to 3 years

  7. Incidence of grade 3+ adverse events

    Toxicities and adverse events (as per Common Terminology for Adverse Events version 5.0) will be summarized by the treatment arms, type, incidence, severity, seriousness, and relatedness. The rate of grade ≥ 3 AEs will be summarized as proportions with 90% Clopper Pearson confidence intervals.

    Time frame: Up to 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2029, 30 months later.

Of 285 non-industry phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 113. This study's planned 30 months is below that.

Counting every sponsor, half of 362 studies reached it within 65 months; a quarter within 34 and three quarters within 102.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 22, 2026
StartEst.
Dec 1, 2026was Sep 2026
Primary completionEst.
Jun 25, 2029
CompletionEst.
Sep 1, 2029
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Dec 1, 2026
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Start date Sep 1, 2026→Dec 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07718672
Responsible party
Sponsor
First posted
Jul 22, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jun 25, 2029 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Nov 5, 2026

Study contacts

Mark Farrugia
principal investigator · Roswell Park Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion